Cargando…

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3

PURPOSE: The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined. Radiotherapy might be superior to temozolomide. Recent studies have linked temozolomide with induction of hypermutation and poor clinical course in some ID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weller, Jonathan, Katzendobler, Sophie, Blobner, Jens, Thiele, Frederic, Becker, Hannes, Quach, Stefanie, Egensperger, Rupert, Niyazi, Maximilian, Suchorska, Bogdana, Thon, Niklas, Weller, Michael, Tonn, Joerg-Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622511/ https://www.ncbi.nlm.nih.gov/pubmed/36112301 http://dx.doi.org/10.1007/s11060-022-04128-y

Ejemplares similares

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
por: Weller, Jonathan, et al.
Publicado: (2021)

Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas
por: Katzendobler, Sophie, et al.
Publicado: (2022)

The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine
por: Katzendobler, Sophie, et al.
Publicado: (2022)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status
por: Weller, Jonathan, et al.
Publicado: (2023)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers
por: Karschnia, Philipp, et al.
Publicado: (2021)

Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
por: Lietke, Stefanie, et al.
Publicado: (2021)

Intramedullary pilomyxoid astrocytoma with intracerebral metastasis exhibiting oligoden-droglioma-like features
por: Eigenbrod, Sabina, et al.
Publicado: (2012)

Combination of pre-treatment dynamic [(18)F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
por: Li, Zhicong, et al.
Publicado: (2022)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas
por: Biczok, Annamaria, et al.
Publicado: (2021)

Early treatment of complex located pediatric low‐grade gliomas using iodine‐125 brachytherapy alone or in combination with microsurgery
por: Kunz, Mathias, et al.
Publicado: (2015)

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

Dorsal column mapping in resection of intramedullary spinal cord tumors: a prospective comparison of two methods and neurological follow-up
por: Ueberschaer, Moritz, et al.
Publicado: (2023)

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma
por: Minniti, Giuseppe, et al.
Publicado: (2023)

Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
por: Blobner, Jens, et al.
Publicado: (2023)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas
por: Omar, Ayman I, et al.
Publicado: (2010)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
por: Fujimaki, Takamitsu, et al.
Publicado: (2007)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Iodine-125 brachytherapy for brain tumours - a review
por: Schwarz, Silke B, et al.
Publicado: (2012)

Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide
por: WU, HAO, et al.
Publicado: (2013)

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
por: Gwak, Ho-Shin, et al.
Publicado: (2013)

Development of Aplastic Anemia during Treatment of Anaplastic Astrocytoma with Temozolomide
por: Khaddour, Karam, et al.
Publicado: (2020)

The surgical perspective in precision treatment of diffuse gliomas
por: Thon, Niklas, et al.
Publicado: (2019)

Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma
por: Teske, Nico, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b749eefkq7i3umdijfth3rlgj7